Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-03 in meibomian gland dysfunction with Demodex
NCT05454956Phase 2Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lotilaner in meibomian gland dysfunction (MGD), blepharitis, demodicosis, sponsored by Tarsus Pharmaceuticals, Inc.. Started Aug 2022; status: completed.
02
Drugs
lotilaner
03
Conditions
meibomian gland dysfunction (MGD)blepharitisdemodicosis
Beyond the preview
Go deeper on NCT05454956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454956.